1. Phylogeny  
   Cyclin-dependent kinase 7 (CDK7) is evolutionarily conserved across eukaryotic species and belongs to the cyclin-dependent kinase family, which is itself a part of the larger CMGC group of serine/threonine kinases. In particular, CDK7 is classified as a transcriptional CDK with dual functions—serving as both the CDK-activating kinase (CAK) and a regulator of RNA polymerase II–mediated transcription—that distinguishes it from other cell cycle CDKs (duster2021biochemicalcharacterizationofa pages 11-15). The orthologs for CDK7 have been identified in yeasts, such as the budding yeast Kin28 and the fission yeast Mcs6, although notable differences exist in their CAK activities when compared to human CDK7 (isa2017theroleof pages 20-23, pluta2024cyclin‐dependentkinasesmasters pages 3-5). Phylogenetic studies trace the CDK7 gene back to the Last Eukaryotic Common Ancestor (LECA), underscoring its indispensable role in both cell cycle progression and transcription regulation throughout evolution (duster2024structuralbasisof pages 1-4, pluta2024cyclin‐dependentkinasesmasters pages 28-29). In mammals, CDK7 orthologs are highly conserved in sequence and functional domains, indicating the preservation of key catalytic and regulatory mechanisms that are central to its activity (pluta2024cyclin‐dependentkinasesmasters pages 36-37). In summary, CDK7’s membership in the transcriptional CDK subfamily, its evolutionary conservation from yeast to human, and its integration into basal transcription machinery highlight its role as a central regulator in eukaryotic cells (duster2021biochemicalcharacterizationof pages 11-15).
2. Reaction Catalyzed  
   CDK7 functions as a serine/threonine kinase that catalyzes the transfer of the γ-phosphate group from ATP to specific hydroxyl residues on substrate proteins – a reaction that converts ATP to ADP while phosphorylating the target protein. This reaction can be succinctly summarized as: ATP + protein (on serine/threonine) → ADP + protein-P + H⁺ (duster2021biochemicalcharacterizationofa pages 23-28). In its role as a CDK-activating kinase (CAK), CDK7 phosphorylates the T-loop activation segments of other cyclin-dependent kinases such as CDK1, CDK2, CDK4, CDK6, and even transcription-related kinases like CDK9 – modifications that are critical for the full activation of these kinases (duster2021biochemicalcharacterizationofa pages 11-15, duster2021biochemicalcharacterizationofb pages 11-15). Additionally, when functioning as part of the general transcription factor TFIIH, CDK7 phosphorylates the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II (POLR2A) predominantly at serine 5 and serine 7 residues within the heptapeptide repeats, thereby promoting promoter clearance and transition into productive elongation during transcription (fisher2019cdk7akinase pages 1-3, isa2017theroleof pages 20-23). The reaction mechanism involves precise positioning of the substrate protein within the catalytic domain, coordinated by ATP-binding and the proper alignment of key catalytic residues (duster2021biochemicalcharacterizationof pages 56-60).
3. Cofactor Requirements  
   The catalytic activity of CDK7 is dependent upon several essential cofactors. Most notably, like other kinases, CDK7 requires ATP as the phosphate donor for its phosphorylation reactions (duster2021biochemicalcharacterizationofa pages 56-60). In addition to ATP, divalent metal ions—primarily magnesium (Mg²⁺)—are necessary to coordinate the binding of ATP within the active site and stabilize the transition state during phosphoryl transfer (duster2021biochemicalcharacterizationofb pages 56-60). Other regulatory partners also function effectively as structural cofactors; for example, the formation of a ternary complex with cyclin H and MAT1 is essential for attaining full catalytic activity and proper substrate recognition by CDK7 (duster2021biochemicalcharacterizationofa pages 11-15, galbraith2019therapeutictargetingof pages 6-7). Thus, the complex formation with cyclin H and MAT1 acts in a manner analogous to a cofactor, as it modulates the conformation of the kinase to enable efficient catalysis (duster2021biochemicalcharacterizationof pages 81-86).
4. Substrate Specificity  
   CDK7 exhibits a distinct substrate specificity that reflects its dual roles in both cell cycle regulation and transcription. In its CAK function, CDK7 phosphorylates the T-loop threonine residues on other cyclin-dependent kinases – for instance, phosphorylation of CDK1 at Thr161, CDK2 at Thr160, as well as the corresponding T-loop residues in CDK4 and CDK6 – thereby effectuating their transition from inactive to active states (duster2021biochemicalcharacterizationofa pages 11-15, duster2021biochemicalcharacterizationofb pages 122-124).  
   In its role as a transcriptional kinase, CDK7 primarily targets the C-terminal domain (CTD) of RNA polymerase II, which consists of multiple heptapeptide repeats with the consensus sequence Y₁S₂P₃T₄S₅P₆S₇. The phosphorylation events occur predominantly at serine residues, notably Ser5 and Ser7, which are crucial for promoter clearance and the transition from transcription initiation to elongation (fisher2019cdk7akinase pages 1-3, isa2017theroleof pages 20-23).  
   Additional physiological substrates include transcription factors and co-regulators, such as SPT5 (SUPT5H), SF1, and the tumor suppressor p53, whereby phosphorylation can modulate their DNA binding or protein–protein interactions (duster2021biochemicalcharacterizationof pages 81-86, duster2021biochemicalcharacterizationofa pages 122-124). Although a strict consensus phosphorylation motif for CDK7 is less clearly defined compared to some other kinases, the presence of a serine/threonine residue within an appropriate structural context appears to be essential, and substrate selection is further influenced by complex formation with cyclin H and MAT1 (parua2020dissectingthepol pages 3-4, pellarin2025cyclindependentproteinkinases pages 9-10).
5. Structure  
   CDK7 has a modular structure comprising a well‐conserved central kinase domain flanked by shorter N‐ and C‐terminal segments that are thought to play roles in subcellular localization and regulatory interactions. The kinase domain is composed of two lobes—an N-terminal lobe primarily made up of β-sheets and an α-helical C-terminal lobe—and these are connected by a flexible linker that forms the active site cleft, where ATP binds and substrates are accommodated (duster2021biochemicalcharacterizationofb pages 56-60, liang2021recentprogressin pages 1-6).  
   A distinguishing structural feature of CDK7, compared to other CDKs, is the variant cyclin-binding motif; unlike the canonical PSTAIRE motif found in other members of the family, CDK7 exhibits a modified sequence (NRTALRE) that influences its interaction with its cyclin partner, Cyclin H (duster2021biochemicalcharacterizationof pages 56-60, pluta2024cyclin‐dependentkinasesmasters pages 28-29). The formation of the trimeric complex with Cyclin H and MAT1 is critical for full catalytic activity. In this complex, Cyclin H interacts extensively with the N-terminal lobe of CDK7, inducing a conformational rearrangement—most notably the reorientation of the αC-helix—that is necessary to create an open and accessible active site (duster2021biochemicalcharacterizationof pages 81-86, fisher2019cdk7akinase pages 1-3).  
   MAT1, an essential assembly factor, binds to both CDK7 and Cyclin H; rather than exerting regulatory effects on its own, MAT1 functions predominantly as a scaffold that stabilizes the trimeric complex and enhances the kinase activity toward transcriptional substrates (duster2021biochemicalcharacterizationofb pages 56-60, pluta2024cyclin‐dependentkinasesmasters pages 36-37).  
   Structural investigations using crystallography and nano differential scanning fluorimetry (nanoDSF) have provided insights into the conformational stability of the CDK7 complex and revealed that phosphorylation of key T-loop residues, including Thr170 and Ser164, is critical for maintaining the active configuration (duster2021biochemicalcharacterizationofa pages 31-33, duster2024structuralbasisof pages 25-27). Additionally, elements such as putative nuclear localization signals within the N- and C-terminal regions may contribute to the nuclear targeting of CDK7 although these have not been experimentally validated in detail (gong2024cdk7inbreast pages 1-2).
6. Regulation  
   CDK7 is regulated at multiple levels, encompassing both post-translational modifications and complex formation with its regulatory partners. A key regulatory mechanism for CDK7 involves phosphorylation within its activation segment (T-loop), where two principal sites—Ser164 and Thr170—are modified. Thr170 represents the canonical activation site, and its phosphorylation is crucial for achieving a conformation that promotes Cyclin H binding and optimizes substrate recognition, particularly for transcription-related substrates such as RNA polymerase II CTD (duster2021biochemicalcharacterizationofa pages 31-33, duster2024structuralbasisof pages 25-27). Phosphorylation at Ser164, which lies within a consensus site for CDK/MAPK kinases, further stabilizes the complex formation with Cyclin H and MAT1, and fluctuations in Ser164 phosphorylation are associated with specific cell cycle stages or developmental cues (duster2021biochemicalcharacterizationof pages 81-86, pluta2024cyclin‐dependentkinasesmasters pages 36-37).  
   The assembly of CDK7 with Cyclin H and MAT1 itself is an essential regulatory event. Unlike other CDKs that form transient complexes with their cyclin partners, CDK7 forms a highly stable trimeric CAK complex, which in turn can be incorporated into the larger TFIIH complex. This association not only ensures full activation of CDK7 but also provides a direct link between cell cycle regulation and transcription initiation (duster2021biochemicalcharacterizationofa pages 11-15, fisher2019cdk7akinase pages 1-3).  
   Additional regulatory inputs include interactions with other proteins such as XPD, a TFIIH subunit, which can influence the cellular localization of CDK7 and possibly modulate substrate access during DNA repair pathways (duster2021biochemicalcharacterizationofa pages 56-60, isa2017theroleof pages 20-23). Moreover, the absence of autophosphorylation capability in CDK7 suggests that its activation is reliant on other kinases, such as CDK1 or CDK2, to phosphorylate its T-loop in vitro, although the definitive in vivo activating kinase remains unidentified (duster2021biochemicalcharacterizationofa pages 31-33, parua2020dissectingthepol pages 3-4).
7. Function  
   CDK7 plays a central role in controlling fundamental cellular processes by virtue of its dual functionality. As a CDK-activating kinase (CAK), CDK7 phosphorylates and activates key cell cycle regulators—namely CDK1, CDK2, CDK4, and CDK6—by targeting specific threonine residues within their T-loop activation segments. This phosphorylation is a prerequisite for the full activation of these kinases and is essential for driving transitions between critical phases of the cell cycle such as the G1/S and G2/M transitions (duster2021biochemicalcharacterizationofa pages 11-15, pellarin2025cyclindependentproteinkinases pages 9-10).  
   In parallel, CDK7 functions as an integral component of the basal transcription machinery. Incorporated into the general transcription factor TFIIH, CDK7 phosphorylates the C-terminal domain (CTD) of RNA polymerase II, predominantly at serine 5 and serine 7 residues, thereby mediating promoter clearance, transcription initiation, and the coupling of RNA processing events such as 5′-capping (fisher2019cdk7akinase pages 1-3, isa2017theroleof pages 20-23). This phosphorylation event serves as a molecular switch that triggers the transition of RNA polymerase II from the pre-initiation complex to the elongation phase of transcription and can also facilitate the dissociation of RNA polymerase II from the DNA template once transcription has been initiated (galbraith2019therapeutictargetingof pages 6-7, parua2020dissectingthepol pages 3-4).  
   CDK7 has been shown to be constitutively expressed and active throughout the cell cycle, reflecting its dual role in both maintaining basal transcription and in coordinating cell cycle progression (duster2021biochemicalcharacterizationofb pages 11-15, milletti2023cyclers’kinasesin pages 2-3). Its substrates extend beyond other CDKs to include transcriptional regulators, such as the elongation factor SPT5, the splicing factor SF1, and even the tumor suppressor p53, where phosphorylation of p53 by CDK7 can enhance its DNA-binding activity and modulate its transcriptional outputs (duster2021biochemicalcharacterizationof pages 122-124, pellarin2025cyclindependentproteinkinases pages 9-10).  
   Functionally, CDK7 thereby links signalling pathways involved in cell proliferation, DNA damage response, and stress responses with the regulation of gene expression, ensuring that cells coordinate growth and division with proper transcriptional homeostasis (duster2021biochemicalcharacterizationofa pages 11-15, liang2021recentprogressin pages 1-6). This central role makes CDK7 an attractive target for pharmacological intervention, particularly in cancers where dysregulated transcriptional programs and aberrant cell cycle progression are hallmarks of malignant transformation (gong2024cdk7inbreast pages 1-2).
8. Other Comments  
   The therapeutic targeting of CDK7 has attracted significant interest due to its pivotal role in both cell cycle regulation and transcriptional control. Several small-molecule inhibitors have been developed, with covalent inhibitors such as THZ1 and the more selective YKL-5-124 demonstrating potent anticancer activity in preclinical models by specifically targeting the unique cysteine residue within the ATP-binding site of CDK7 (galbraith2019therapeutictargetingof pages 6-7, sava2020cdk7inhibitorsas pages 9-10). These inhibitors work by reducing the phosphorylation of downstream substrates, thereby inducing cell cycle arrest—typically in the G1 phase—and impairing transcription, which can lead to apoptosis in cancer cells that exhibit transcriptional addiction (teng2019recentadvancesin pages 11-15, duster2021biochemicalcharacterizationofb pages 81-86).  
   Disease associations of CDK7 are predominantly observed in various cancers, including triple-negative breast cancer, neuroblastoma, ovarian cancer, and certain hormone-dependent cancers, where elevated CDK7 expression and activity have been correlated with poor prognosis and aggressive tumor phenotypes (gong2024cdk7inbreast pages 1-2, pellarin2025cyclindependentproteinkinases pages 9-10). Although specific mutations in the CDK7 gene are not extensively detailed in the available literature, dysregulation of its activity—whether by overexpression, altered phosphorylation dynamics, or compromised complex formation with Cyclin H/MAT1—has significant implications for tumorigenesis and therapeutic resistance (naro2021oncogenicdysregulationof pages 7-8, duster2021biochemicalcharacterizationof pages 122-124).  
   In ongoing research, the precise mechanisms governing CDK7 activation, its substrate specificity in diverse cellular contexts, and its interplay with transcription factors and the DNA repair machinery are areas of active investigation (duster2024structuralbasisof pages 1-4, parua2020dissectingthepol pages 3-4). Furthermore, detailed structural studies continue to reveal how the unique sequence variations in the cyclin-binding regions and T-loop residues contribute to the differential regulation of CDK7 compared to other CDKs (pluta2024cyclin‐dependentkinasesmasters pages 3-5, duster2021biochemicalcharacterizationofb pages 56-60).  
   Finally, the development of more potent and selective CDK7 inhibitors is an area of intense pharmaceutical interest, with the aim of achieving effective cancer therapy while minimizing off-target effects. Resources such as the Chemical Probes portal and the NIH kinase inhibitor databases are valuable for comparing the efficacy and specificity of these inhibitors, and continued efforts in medicinal chemistry and chemical biology are expected to further refine these therapeutic agents (teng2019recentadvancesin pages 15-18, sava2020cdk7inhibitorsas pages 1-2).
9. References

* brauns2017investigationofthe pages 39-43
* duster2021biochemicalcharacterizationof pages 28-31
* duster2021biochemicalcharacterizationof pages 56-60
* duster2021biochemicalcharacterizationof pages 81-86
* duster2021biochemicalcharacterizationofa pages 11-15
* duster2021biochemicalcharacterizationofa pages 122-124
* duster2021biochemicalcharacterizationofa pages 28-31
* duster2021biochemicalcharacterizationofa pages 81-86
* duster2021biochemicalcharacterizationofb pages 122-124
* duster2021biochemicalcharacterizationofb pages 28-31
* duster2021biochemicalcharacterizationofb pages 56-60
* duster2021biochemicalcharacterizationofb pages 81-86
* duster2024structuralbasisof pages 1-4
* fisher2019cdk7akinase pages 1-3
* galbraith2019therapeutictargetingof pages 6-7
* gong2024cdk7inbreast pages 1-2
* isa2017theroleof pages 20-23
* liang2021recentprogressin pages 1-6
* naro2021oncogenicdysregulationof pages 7-8
* pellarin2025cyclindependentproteinkinases pages 20-21
* pellarin2025cyclindependentproteinkinases pages 9-10
* pluta2024cyclin‐dependentkinasesmasters pages 20-22
* pluta2024cyclin‐dependentkinasesmasters pages 22-23
* pluta2024cyclin‐dependentkinasesmasters pages 28-29
* pluta2024cyclin‐dependentkinasesmasters pages 36-37
* sava2020cdk7inhibitorsas pages 1-2
* sava2020cdk7inhibitorsas pages 2-4
* sava2020cdk7inhibitorsas pages 9-10
* teng2019recentadvancesin pages 11-15
* teng2019recentadvancesin pages 15-18
* teng2019recentadvancesin pages 5-8
* łukasik2021cyclindependentkinases(cdk) pages 4-5
* chowdhury2023cmgckinasesin pages 21-22
* duster2021biochemicalcharacterizationof pages 11-15
* duster2021biochemicalcharacterizationof pages 122-124
* duster2021biochemicalcharacterizationof pages 23-28
* duster2021biochemicalcharacterizationofa pages 23-28
* duster2021biochemicalcharacterizationofa pages 31-33
* duster2021biochemicalcharacterizationofa pages 56-60
* duster2021biochemicalcharacterizationofb pages 11-15
* duster2021biochemicalcharacterizationofb pages 23-28
* duster2021biochemicalcharacterizationofb pages 31-33
* duster2024structuralbasisof pages 25-27
* kumar2021identificationofcdk7 pages 20-21
* liang2021recentprogressin pages 6-9
* milletti2023cyclers’kinasesin pages 2-3
* parua2020dissectingthepol pages 3-4
* pellarin2025cyclindependentproteinkinases pages 2-4
* pluta2024cyclin‐dependentkinasesmasters pages 12-14
* pluta2024cyclin‐dependentkinasesmasters pages 3-5

References

1. (brauns2017investigationofthe pages 39-43): P Brauns. Investigation of the regulation of the histone acetyltransferase tip60 by phosphorylation. Unknown journal, 2017.
2. (duster2021biochemicalcharacterizationof pages 28-31): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
3. (duster2021biochemicalcharacterizationof pages 56-60): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
4. (duster2021biochemicalcharacterizationof pages 81-86): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
5. (duster2021biochemicalcharacterizationofa pages 11-15): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
6. (duster2021biochemicalcharacterizationofa pages 122-124): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
7. (duster2021biochemicalcharacterizationofa pages 28-31): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
8. (duster2021biochemicalcharacterizationofa pages 81-86): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
9. (duster2021biochemicalcharacterizationofb pages 122-124): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
10. (duster2021biochemicalcharacterizationofb pages 28-31): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
11. (duster2021biochemicalcharacterizationofb pages 56-60): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
12. (duster2021biochemicalcharacterizationofb pages 81-86): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
13. (duster2024structuralbasisof pages 1-4): Robert Düster, Kanchan Anand, Sophie C. Binder, Maximilian Schmitz, Karl Gatterdam, Robert P. Fisher, and Matthias Geyer. Structural basis of cdk7 activation by dual t-loop phosphorylation. BioRxiv, Feb 2024. URL: https://doi.org/10.1101/2024.02.14.580246, doi:10.1101/2024.02.14.580246. This article has 9 citations.
14. (fisher2019cdk7akinase pages 1-3): Robert P. Fisher. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery. Transcription, 10:47-56, Dec 2019. URL: https://doi.org/10.1080/21541264.2018.1553483, doi:10.1080/21541264.2018.1553483. This article has 132 citations and is from a peer-reviewed journal.
15. (galbraith2019therapeutictargetingof pages 6-7): Matthew D. Galbraith, Heather Bender, and Joaquín M. Espinosa. Therapeutic targeting of transcriptional cyclin-dependent kinases. Transcription, 10:118-136, Nov 2019. URL: https://doi.org/10.1080/21541264.2018.1539615, doi:10.1080/21541264.2018.1539615. This article has 96 citations and is from a peer-reviewed journal.
16. (gong2024cdk7inbreast pages 1-2): Ying Gong and Huiping Li. Cdk7 in breast cancer: mechanisms of action and therapeutic potential. Cell Communication and Signaling, Apr 2024. URL: https://doi.org/10.1186/s12964-024-01577-y, doi:10.1186/s12964-024-01577-y. This article has 9 citations and is from a peer-reviewed journal.
17. (isa2017theroleof pages 20-23): NF Isa. The role of the hsv-1 icp22 protein in regulation of expression of host cell genes. Unknown journal, 2017.
18. (liang2021recentprogressin pages 1-6): Hanzhi Liang, Jintong Du, Reham M. Elhassan, Xuben Hou, and Hao Fang. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. Expert Opinion on Investigational Drugs, 30:61-76, Jan 2021. URL: https://doi.org/10.1080/13543784.2021.1850693, doi:10.1080/13543784.2021.1850693. This article has 16 citations and is from a peer-reviewed journal.
19. (naro2021oncogenicdysregulationof pages 7-8): Chiara Naro, Pamela Bielli, and Claudio Sette. Oncogenic dysregulation of pre‐mrna processing by protein kinases: challenges and therapeutic opportunities. The FEBS Journal, 288:6250-6272, Jun 2021. URL: https://doi.org/10.1111/febs.16057, doi:10.1111/febs.16057. This article has 39 citations.
20. (pellarin2025cyclindependentproteinkinases pages 20-21): Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, Ilenia Segatto, Valentina Rossi, Nicole Crestan, Javad Karimbayli, Barbara Belletti, and Gustavo Baldassarre. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, Jan 2025. URL: https://doi.org/10.1038/s41392-024-02080-z, doi:10.1038/s41392-024-02080-z. This article has 20 citations and is from a peer-reviewed journal.
21. (pellarin2025cyclindependentproteinkinases pages 9-10): Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, Ilenia Segatto, Valentina Rossi, Nicole Crestan, Javad Karimbayli, Barbara Belletti, and Gustavo Baldassarre. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, Jan 2025. URL: https://doi.org/10.1038/s41392-024-02080-z, doi:10.1038/s41392-024-02080-z. This article has 20 citations and is from a peer-reviewed journal.
22. (pluta2024cyclin‐dependentkinasesmasters pages 20-22): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 19 citations.
23. (pluta2024cyclin‐dependentkinasesmasters pages 22-23): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 19 citations.
24. (pluta2024cyclin‐dependentkinasesmasters pages 28-29): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 19 citations.
25. (pluta2024cyclin‐dependentkinasesmasters pages 36-37): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 19 citations.
26. (sava2020cdk7inhibitorsas pages 1-2): Georgina P. Sava, Hailing Fan, R. Charles Coombes, Lakjaya Buluwela, and Simak Ali. Cdk7 inhibitors as anticancer drugs. Cancer and Metastasis Reviews, 39:805-823, May 2020. URL: https://doi.org/10.1007/s10555-020-09885-8, doi:10.1007/s10555-020-09885-8. This article has 180 citations and is from a peer-reviewed journal.
27. (sava2020cdk7inhibitorsas pages 2-4): Georgina P. Sava, Hailing Fan, R. Charles Coombes, Lakjaya Buluwela, and Simak Ali. Cdk7 inhibitors as anticancer drugs. Cancer and Metastasis Reviews, 39:805-823, May 2020. URL: https://doi.org/10.1007/s10555-020-09885-8, doi:10.1007/s10555-020-09885-8. This article has 180 citations and is from a peer-reviewed journal.
28. (sava2020cdk7inhibitorsas pages 9-10): Georgina P. Sava, Hailing Fan, R. Charles Coombes, Lakjaya Buluwela, and Simak Ali. Cdk7 inhibitors as anticancer drugs. Cancer and Metastasis Reviews, 39:805-823, May 2020. URL: https://doi.org/10.1007/s10555-020-09885-8, doi:10.1007/s10555-020-09885-8. This article has 180 citations and is from a peer-reviewed journal.
29. (teng2019recentadvancesin pages 11-15): Yuou Teng, Kui Lu, Qian Zhang, Lianbo Zhao, Yuna Huang, Angela Maria Ingarra, Hervé Galons, Tingshen Li, Shanshan Cui, Peng Yu, and Nassima Oumata. Recent advances in the development of cyclin-dependent kinase 7 inhibitors. European Journal of Medicinal Chemistry, 183:111641, Dec 2019. URL: https://doi.org/10.1016/j.ejmech.2019.111641, doi:10.1016/j.ejmech.2019.111641. This article has 27 citations and is from a domain leading peer-reviewed journal.
30. (teng2019recentadvancesin pages 15-18): Yuou Teng, Kui Lu, Qian Zhang, Lianbo Zhao, Yuna Huang, Angela Maria Ingarra, Hervé Galons, Tingshen Li, Shanshan Cui, Peng Yu, and Nassima Oumata. Recent advances in the development of cyclin-dependent kinase 7 inhibitors. European Journal of Medicinal Chemistry, 183:111641, Dec 2019. URL: https://doi.org/10.1016/j.ejmech.2019.111641, doi:10.1016/j.ejmech.2019.111641. This article has 27 citations and is from a domain leading peer-reviewed journal.
31. (teng2019recentadvancesin pages 5-8): Yuou Teng, Kui Lu, Qian Zhang, Lianbo Zhao, Yuna Huang, Angela Maria Ingarra, Hervé Galons, Tingshen Li, Shanshan Cui, Peng Yu, and Nassima Oumata. Recent advances in the development of cyclin-dependent kinase 7 inhibitors. European Journal of Medicinal Chemistry, 183:111641, Dec 2019. URL: https://doi.org/10.1016/j.ejmech.2019.111641, doi:10.1016/j.ejmech.2019.111641. This article has 27 citations and is from a domain leading peer-reviewed journal.
32. (łukasik2021cyclindependentkinases(cdk) pages 4-5): Paweł Łukasik, Michał Załuski, and Izabela Gutowska. Cyclin-dependent kinases (cdk) and their role in diseases development–review. International Journal of Molecular Sciences, 22:2935, Mar 2021. URL: https://doi.org/10.3390/ijms22062935, doi:10.3390/ijms22062935. This article has 198 citations and is from a peer-reviewed journal.
33. (chowdhury2023cmgckinasesin pages 21-22): Iftekhar Chowdhury, Giovanna Dashi, and Salla Keskitalo. Cmgc kinases in health and cancer. Cancers, 15:3838, Jul 2023. URL: https://doi.org/10.3390/cancers15153838, doi:10.3390/cancers15153838. This article has 18 citations and is from a peer-reviewed journal.
34. (duster2021biochemicalcharacterizationof pages 11-15): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
35. (duster2021biochemicalcharacterizationof pages 122-124): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
36. (duster2021biochemicalcharacterizationof pages 23-28): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
37. (duster2021biochemicalcharacterizationofa pages 23-28): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
38. (duster2021biochemicalcharacterizationofa pages 31-33): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
39. (duster2021biochemicalcharacterizationofa pages 56-60): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
40. (duster2021biochemicalcharacterizationofb pages 11-15): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
41. (duster2021biochemicalcharacterizationofb pages 23-28): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
42. (duster2021biochemicalcharacterizationofb pages 31-33): RS Düster. Biochemical characterization of the human cyclin-dependent kinases cdk7 and cdk10. Unknown journal, 2021.
43. (duster2024structuralbasisof pages 25-27): Robert Düster, Kanchan Anand, Sophie C. Binder, Maximilian Schmitz, Karl Gatterdam, Robert P. Fisher, and Matthias Geyer. Structural basis of cdk7 activation by dual t-loop phosphorylation. BioRxiv, Feb 2024. URL: https://doi.org/10.1101/2024.02.14.580246, doi:10.1101/2024.02.14.580246. This article has 9 citations.
44. (kumar2021identificationofcdk7 pages 20-21): Vikas Kumar, Shraddha Parate, Gunjan Thakur, Gihwan Lee, Hyeon-Su Ro, Yongseong Kim, Hong Ja Kim, Myeong Ok Kim, and Keun Woo Lee. Identification of cdk7 inhibitors from natural sources using pharmacoinformatics and molecular dynamics simulations. Biomedicines, 9:1197, Sep 2021. URL: https://doi.org/10.3390/biomedicines9091197, doi:10.3390/biomedicines9091197. This article has 25 citations and is from a peer-reviewed journal.
45. (liang2021recentprogressin pages 6-9): Hanzhi Liang, Jintong Du, Reham M. Elhassan, Xuben Hou, and Hao Fang. Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. Expert Opinion on Investigational Drugs, 30:61-76, Jan 2021. URL: https://doi.org/10.1080/13543784.2021.1850693, doi:10.1080/13543784.2021.1850693. This article has 16 citations and is from a peer-reviewed journal.
46. (milletti2023cyclers’kinasesin pages 2-3): Giacomo Milletti, Valeria Colicchia, and Francesco Cecconi. Cyclers’ kinases in cell division: from molecules to cancer therapy. Cell Death & Differentiation, 30:2035-2052, Jul 2023. URL: https://doi.org/10.1038/s41418-023-01196-z, doi:10.1038/s41418-023-01196-z. This article has 17 citations.
47. (parua2020dissectingthepol pages 3-4): Pabitra K. Parua and Robert P. Fisher. Dissecting the pol ii transcription cycle and derailing cancer with cdk inhibitors. Nature Chemical Biology, 16:716-724, Jun 2020. URL: https://doi.org/10.1038/s41589-020-0563-4, doi:10.1038/s41589-020-0563-4. This article has 87 citations and is from a highest quality peer-reviewed journal.
48. (pellarin2025cyclindependentproteinkinases pages 2-4): Ilenia Pellarin, Alessandra Dall’Acqua, Andrea Favero, Ilenia Segatto, Valentina Rossi, Nicole Crestan, Javad Karimbayli, Barbara Belletti, and Gustavo Baldassarre. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduction and Targeted Therapy, Jan 2025. URL: https://doi.org/10.1038/s41392-024-02080-z, doi:10.1038/s41392-024-02080-z. This article has 20 citations and is from a peer-reviewed journal.
49. (pluta2024cyclin‐dependentkinasesmasters pages 12-14): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 19 citations.
50. (pluta2024cyclin‐dependentkinasesmasters pages 3-5): Aleksandra J. Pluta, Cécilia Studniarek, Shona Murphy, and Chris J. Norbury. Cyclin‐dependent kinases: masters of the eukaryotic universe. WIREs RNA, Sep 2024. URL: https://doi.org/10.1002/wrna.1816, doi:10.1002/wrna.1816. This article has 19 citations.